Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

(2022) E. L. M. ter Haar et al.   DRUGS & AGING

Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study

(2022) Elke L.M. Ter Haar et al.   ACTA DERMATO-VENEREOLOGICA

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

(2022) Athanasios Tsianakas et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Five‐year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)

(2021) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

(2021) A. Ruggiero et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

(2021) Katharina A. Drerup et al.   DERMATOLOGY

Comparison of Biologics and Oral Treatments for Plaque Psoriasis

(2020) April W. Armstrong et al.   JAMA Dermatology

Evaluation of the Frequency of “Not Relevant” Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis

(2020) John S. Barbieri et al.   JAMA Dermatology

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

(2020) Marilyn T. Wan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI‐Relevant (DLQI‐R) scoring

(2020) F. Rencz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Elderly patients with psoriasis: Long-term efficacy and safety of modern treatments

(2020) Katerina Bakirtzi et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups

(2020) M.E.C. Winden et al.   BRITISH JOURNAL OF DERMATOLOGY

Responsiveness of the EQ‐5D‐3L, DLQI, and DLQI‐R for Patients With Psoriasis in the United States

(2019) J. Barbieri et al.   BRITISH JOURNAL OF DERMATOLOGY

Influence of “Not Relevant” Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States

(2019) John S. Barbieri et al.   JAMA Dermatology

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

(2019) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review

(2019) Mirjam J. Schaap et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

DLQI‐R scoring improves the discriminatory power of Dermatology Life Quality Index in psoriasis, pemphigus and morphea patients

(2019) F. Rencz et al.   BRITISH JOURNAL OF DERMATOLOGY

Proposal of a new scoring formula for the DLQI in psoriasis

(2018) F. Rencz et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis and the metabolic syndrome

(2018) Paolo Gisondi et al.   CLINICS IN DERMATOLOGY

Elderly psoriatic patients under biological therapies: an Italian experience

(2018) F Ricceri et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Inappropriate Use of Medication by Elderly, Polymedicated, or Multipathological Patients with Chronic Diseases

(2018) Virtudes Pérez-Jover et al.   International Journal of Environmental Research and Public Health

Prevalence and incidence of psoriasis and psoriatic arthritis

(2018) Philipp Sewerin et al.   ANNALS OF THE RHEUMATIC DISEASES

Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?

(2018) A. Langenbruch et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tildrakizumab: A Review of Phase II and III Clinical Trials

(2018) Sree S. Kolli et al.   ANNALS OF PHARMACOTHERAPY

A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions

(2017) F. Rencz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Adverse drug reactions in special populations - the elderly

(2015) E. A. Davies et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis

(2014) C. Phan et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?

(2011) Hyuck Hoon Kwon et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Safety of treatment with biologics for psoriasis in daily practice: 5-year data

(2011) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Epidemiology of comorbidities in psoriasis

(2010) Luigi Naldi et al.   Dermatologic Therapy

Heart Disease and Stroke Statistics—2010 Update

(2009) et al.   CIRCULATION